Atossa Genetics Short Interest Surges 56% in January

Biotech firm's stock sees significant increase in short positions amid market volatility

Jan. 31, 2026 at 9:47am

Got story updates? Submit your updates here. ›

Atossa Genetics Inc. (NASDAQ:ATOS), a Seattle-based biotech company, saw a 56.4% increase in short interest during January, with 3.6 million shares now sold short. This represents 3.1% of the company's total outstanding shares. The surge in short positions comes amid ongoing market volatility and uncertainty surrounding the company's pipeline of breast cancer treatments.

Why it matters

The rise in short interest reflects growing skepticism among investors about Atossa Genetics' near-term prospects. As a clinical-stage biotech firm, the company faces significant regulatory hurdles and competition in bringing its therapies to market. The increased short activity could signal that some traders are betting against the stock's performance in the coming months.

The details

According to data from MarketBeat, Atossa Genetics had short interest totaling 3,621,023 shares as of January 15th, up from 2,314,959 shares at the end of December. This represents a 56.4% increase in the number of shares sold short. The short interest ratio, which measures the number of days it would take to cover all the short positions, currently stands at 3.1 days based on the stock's average daily trading volume.

  • As of January 15th, 2026, Atossa Genetics had 3,621,023 shares sold short.
  • This represents a 56.4% increase from the 2,314,959 shares sold short as of December 31st, 2025.

The players

Atossa Genetics Inc.

A clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Atossa Genetics' progress in advancing its pipeline of breast cancer treatments, as well as any updates on the regulatory approval process. The company's stock performance and short interest activity will also be closely monitored by the market.

The takeaway

The surge in short interest in Atossa Genetics reflects the inherent risks and volatility associated with investing in clinical-stage biotech companies. As the company navigates the regulatory landscape and competitive market, its ability to deliver on its pipeline and gain investor confidence will be crucial in determining the stock's future performance.